Rankings
▼
Calendar
ESPR Q2 2025 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ESPR
Esperion Therapeutics, Inc.
$577M
Q2 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$82M
+11.6% YoY
Gross Profit
$54M
65.4% margin
Operating Income
$7M
8.6% margin
Net Income
-$13M
-15.4% margin
EPS (Diluted)
$-0.02
QoQ Revenue Growth
+26.8%
Cash Flow
Operating Cash Flow
-$31M
Free Cash Flow
-$31M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$347M
Total Liabilities
$781M
Stockholders' Equity
-$434M
Cash & Equivalents
$86M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$82M
$74M
+11.6%
Gross Profit
$54M
$58M
-7.5%
Operating Income
$7M
$3M
+175.1%
Net Income
-$13M
-$62M
+79.5%
Revenue Segments
Collaboration Revenue
$42M
51%
Product
$40M
49%
← Q1 2025
All Quarters
Q3 2025 →